China cardiovascular drugs market set to grow to 45 billion renminbi by 2018
A new report titled Research on China Cardiovascular Drugs Industry 2014-2018, says that, in the next 10 years, there is a potential for the growth in cardiovascular diseases treatment field.
It is predicted that the growth rate will be of more than 20% from 2014 to 2018. This report, added to the offering of MarketReportsChina.com, estimates that the sales of cardiovascular drugs in China in 2014 will reach about 22 billion renminbi ($3.52 billion), and the figure will be 45 billion renminbi by 2018.
With the aged tendency of population in China and the increasing morbidity of chronic diseases which have to be treated with medicines for the rest of patients' life, the market scale of cardiovascular drugs is expanding. This trend has been reflected in recent years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze